Global Squamous Non-Small Cell Lung Cancer Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
SKU ID : QYR-21658048 | Publishing Date : 12-Sep-2022 | No. of pages : 119
Detailed TOC of Global Squamous Non-Small Cell Lung Cancer Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 BMS-906024
1.2.3 Buparlisib Hydrochloride
1.2.4 FP-1039
1.2.5 Ipilimumab
1.2.6 JNJ-42756493
1.2.7 Lenvatinib
1.2.8 Others
1.3 Market by Application
1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Research Center
1.3.3 Hospital
1.3.4 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2017-2028)
2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2017-2022)
2.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2023-2028)
2.5 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Countries Ranking by Market Size
3 Squamous Non-Small Cell Lung Cancer Therapeutics Competitive by Company
3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players
3.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2017-2022)
3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2017-2022)
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2021
3.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Revenue by Type (2017-2022)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Revenue by Type (2023-2028)
5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022)
6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022)
7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022)
8.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
8.3 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
8.4 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022)
9.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
9.3 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
9.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022)
10.2 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
10.3 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
10.4 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Ascenta Therapeutics, Inc.
11.1.1 Ascenta Therapeutics, Inc. Company Details
11.1.2 Ascenta Therapeutics, Inc. Business Overview
11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.1.5 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.1.6 Ascenta Therapeutics, Inc. Recent Developments
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Company Details
11.2.2 AstraZeneca Plc Business Overview
11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.2.5 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.2.6 AstraZeneca Plc Recent Developments
11.3 AVEO Pharmaceuticals, Inc.
11.3.1 AVEO Pharmaceuticals, Inc. Company Details
11.3.2 AVEO Pharmaceuticals, Inc. Business Overview
11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.3.5 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.3.6 AVEO Pharmaceuticals, Inc. Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.4.5 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.4.6 Bayer AG Recent Developments
11.5 BIND Therapeutics, Inc.
11.5.1 BIND Therapeutics, Inc. Company Details
11.5.2 BIND Therapeutics, Inc. Business Overview
11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.5.5 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.5.6 BIND Therapeutics, Inc. Recent Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Company Details
11.6.2 Boehringer Ingelheim GmbH Business Overview
11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.6.5 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.6.6 Boehringer Ingelheim GmbH Recent Developments
11.7 Bristol-Myers Squibb Company
11.7.1 Bristol-Myers Squibb Company Company Details
11.7.2 Bristol-Myers Squibb Company Business Overview
11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.7.5 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.7.6 Bristol-Myers Squibb Company Recent Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.8.5 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.8.6 Eli Lilly and Company Recent Developments
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Details
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.9.5 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.9.6 F. Hoffmann-La Roche Ltd. Recent Developments
11.10 Five Prime Therapeutics, Inc.
11.10.1 Five Prime Therapeutics, Inc. Company Details
11.10.2 Five Prime Therapeutics, Inc. Business Overview
11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.10.5 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
11.10.6 Five Prime Therapeutics, Inc. Recent Developments
11.11 Genentech, Inc.
11.11.1 Genentech, Inc. Company Details
11.11.2 Genentech, Inc. Business Overview
11.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.11.5 Genentech, Inc. Recent Developments
11.12 Incyte Corporation
11.12.1 Incyte Corporation Company Details
11.12.2 Incyte Corporation Business Overview
11.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.12.5 Incyte Corporation Recent Developments
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Details
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.13.5 Johnson & Johnson Recent Developments
11.14 MacroGenics, Inc.
11.14.1 MacroGenics, Inc. Company Details
11.14.2 MacroGenics, Inc. Business Overview
11.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.14.5 MacroGenics, Inc. Recent Developments
11.15 Novartis AG
11.15.1 Novartis AG Company Details
11.15.2 Novartis AG Business Overview
11.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.15.5 Novartis AG Recent Developments
11.16 Oncogenex Pharmaceuticals, Inc.
11.16.1 Oncogenex Pharmaceuticals, Inc. Company Details
11.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
11.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments
11.17 PsiOxus Therapeutics Limited
11.17.1 PsiOxus Therapeutics Limited Company Details
11.17.2 PsiOxus Therapeutics Limited Business Overview
11.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Products and Services
11.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
11.17.5 PsiOxus Therapeutics Limited Recent Developments
12 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
12.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
12.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
12.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
12.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Figures, Tables and Charts Available in Global Squamous Non-Small Cell Lung Cancer Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
List of TablesTable 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of BMS-906024
Table 3. Key Players of Buparlisib Hydrochloride
Table 4. Key Players of FP-1039
Table 5. Key Players of Ipilimumab
Table 6. Key Players of JNJ-42756493
Table 7. Key Players of Lenvatinib
Table 8. Key Players of Others
Table 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region (2017-2022)
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2017-2022)
Table 15. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2021)
Table 16. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2021
Table 17. Global 5 Largest Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 18. Key Players Headquarters and Area Served
Table 19. Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
Table 20. Date of Key Manufacturers Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2022)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2023-2028)
Table 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 27. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2022)
Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2023-2028)
Table 30. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 31. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 32. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 33. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 34. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 35. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 36. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 37. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 38. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 39. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 40. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 41. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 42. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 43. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 45. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2023-2028) & (US$ Million)
Table 51. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 52. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 53. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 54. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 55. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 56. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 57. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 59. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 63. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 64. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 65. Ascenta Therapeutics, Inc. Company Details
Table 66. Ascenta Therapeutics, Inc. Business Overview
Table 67. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 68. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 70. Ascenta Therapeutics, Inc. Recent Developments
Table 71. AstraZeneca Plc Company Details
Table 72. AstraZeneca Plc Business Overview
Table 73. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 74. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 75. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 76. AstraZeneca Plc Recent Developments
Table 77. AVEO Pharmaceuticals, Inc. Company Details
Table 78. AVEO Pharmaceuticals, Inc. Business Overview
Table 79. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 80. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 81. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 82. AVEO Pharmaceuticals, Inc. Recent Developments
Table 83. Bayer AG Company Details
Table 84. Bayer AG Business Overview
Table 85. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 86. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 87. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 88. Bayer AG Recent Developments
Table 89. BIND Therapeutics, Inc. Company Details
Table 90. BIND Therapeutics, Inc. Business Overview
Table 91. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 92. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 93. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 94. BIND Therapeutics, Inc. Recent Developments
Table 95. Boehringer Ingelheim GmbH Company Details
Table 96. Boehringer Ingelheim GmbH Business Overview
Table 97. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 98. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 99. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 100. Boehringer Ingelheim GmbH Recent Developments
Table 101. Bristol-Myers Squibb Company Company Details
Table 102. Bristol-Myers Squibb Company Business Overview
Table 103. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 104. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 105. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 106. Bristol-Myers Squibb Company Recent Developments
Table 107. Eli Lilly and Company Company Details
Table 108. Eli Lilly and Company Business Overview
Table 109. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 110. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 111. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 112. Eli Lilly and Company Recent Developments
Table 113. F. Hoffmann-La Roche Ltd. Company Details
Table 114. F. Hoffmann-La Roche Ltd. Business Overview
Table 115. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 116. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 117. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 118. F. Hoffmann-La Roche Ltd. Recent Developments
Table 119. Five Prime Therapeutics, Inc. Company Details
Table 120. Five Prime Therapeutics, Inc. Business Overview
Table 121. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 122. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 123. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 124. Five Prime Therapeutics, Inc. Recent Developments
Table 125. Genentech, Inc. Company Details
Table 126. Genentech, Inc. Business Overview
Table 127. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 128. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 129. Genentech, Inc. Recent Developments
Table 130. Incyte Corporation Company Details
Table 131. Incyte Corporation Business Overview
Table 132. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 133. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 134. Incyte Corporation Recent Developments
Table 135. Johnson & Johnson Company Details
Table 136. Johnson & Johnson Business Overview
Table 137. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 138. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 139. Johnson & Johnson Recent Developments
Table 140. MacroGenics, Inc. Company Details
Table 141. MacroGenics, Inc. Business Overview
Table 142. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 143. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 144. MacroGenics, Inc. Recent Developments
Table 145. Novartis AG Company Details
Table 146. Novartis AG Business Overview
Table 147. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 148. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 149. Novartis AG Recent Developments
Table 150. Oncogenex Pharmaceuticals, Inc. Company Details
Table 151. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 152. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 153. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 154. Oncogenex Pharmaceuticals, Inc. Recent Developments
Table 155. PsiOxus Therapeutics Limited Company Details
Table 156. PsiOxus Therapeutics Limited Business Overview
Table 157. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product and Services
Table 158. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 159. PsiOxus Therapeutics Limited Recent Developments
Table 160. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 161. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Table 162. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 163. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type: 2021 VS 2028
Figure 2. BMS-906024 Features
Figure 3. Buparlisib Hydrochloride Features
Figure 4. FP-1039 Features
Figure 5. Ipilimumab Features
Figure 6. JNJ-42756493 Features
Figure 7. Lenvatinib Features
Figure 8. Others Features
Figure 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application: 2021 VS 2028
Figure 10. Research Center Case Studies
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2017-2028 (US$ Million)
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Market Share by Region: 2021 VS 2028
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region in 2017 VS 2022
Figure 18. Global Top 10 Squamous Non-Small Cell Lung Cancer Therapeutics Countries Ranking by Market Size (US$ Million) in 2021
Figure 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players in 2021
Figure 20. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2021
Figure 22. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company in 2021
Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2028)
Figure 24. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2028)
Figure 25. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Country (2017-2028)
Figure 26. U.S. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 27. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 28. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company in 2021
Figure 29. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2028)
Figure 30. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2028)
Figure 31. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Country (2017-2028)
Figure 32. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 33. France Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 34. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 35. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 36. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 37. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company in 2021
Figure 38. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2028)
Figure 39. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2028)
Figure 40. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Region (2017-2028)
Figure 41. China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 42. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 43. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 44. India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 45. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 46. Taiwan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 47. Indonesia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 48. Thailand Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 49. Malaysia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 50. Philippines Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 51. Vietnam Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 52. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company in 2021
Figure 53. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2028)
Figure 54. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2028)
Figure 55. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Country (2017-2028)
Figure 56. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 57. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 58. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 59. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Company in 2021
Figure 60. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2017-2028)
Figure 61. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2028)
Figure 62. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Country (2017-2028)
Figure 63. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 64. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 65. U.A.E Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 66. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 67. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 68. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 69. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 70. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 71. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 72. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 73. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 74. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 75. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 76. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 77. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 78. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 79. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 80. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 81. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 82. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed
Keyplayers in Global Squamous Non-Small Cell Lung Cancer Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Ascenta Therapeutics, Inc.AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
24/7 Research Support
Phone: +1 424 253 0807 
